Anton Rx Report

Today we are pleased to offer a review of an article from which just about anyone working in the specialty pharmacy segment might learn something…. or

The rate of FDA approvals of gene therapies is picking up….. at a pace not too dissimilar to the bevy of biosimilars we’ve witnessed in

……. continuing to catch up on FDA approvals The FDA recently approved a biosimilar, Simlandi (adalimumab-ryvk) from Alvotech and Teva Pharmaceuticals, as a biosimilar to

There were no big surprises in the recently published list of the Top 15 specialty pharmacies nationally. That is if you only look at the ranking

The FDA recently approved a ‘two-fer’…. yep, TWO identical biosimilars with the approval of Jubbonti (denosumab-bbdz) and Wyost (denosumab-bbdz) from Sandoz, Inc. They are the same

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the early press releases

The FDA recently approved yet another – first in class -cellular therapy, Amtagvi (lifileucel) from Iovance Biotherapeutics Inc., indicated for the treatment of adult patients

It is not often that I see a report of an event that is so extraordinary that it is jaw dropping. A report that BioPlus Specialty

……..catching up on FDA approvals The FDA recently approved a new form of Eohilia (budesonide oral suspension) from Takeda , the first and only FDA-approved

……..catching up on FDA Approvals The FDA recently approved a new infused therapy, Avzivi (bevacizumab-tnjn) from Bio-Thera Solutions, as a biosimilar to AVASTIN (bevacizumab). It did not receive